<DOC>
	<DOCNO>NCT02831088</DOCNO>
	<brief_summary>Efficacy safety Neu2000 , multi-target drug design prevent NMDA receptor-mediated excitotoxicity free radical toxicity , investigate acute ischemic stroke patient receive endovascular treatment remove clot within 8 hour follow stroke onset . Neu2000KWL administer endovascular treatment .</brief_summary>
	<brief_title>Efficacy Safety Neu2000KWL Treating Acute Ischemic Stroke Receiving Endovascular Therapy ( ENIS I )</brief_title>
	<detailed_description>Neu2000 design multi-target neuroprotectant prevent NMDA receptor , Ca2+-permeable glutamate receptor , free radical , two major route brain cell death stroke . Neu2000 moderate NR2B-selective NMDA receptor antagonist spin trap molecule ( =free radical scavenger antioxidant ) . Therapeutic potential Neu2000 well demonstrate four animal model stroke good efficacy therapeutic time windows either NMDA receptor antagonist anti-oxidant advanced clinical trial . In human phase I study 165 healthy subject conduct United States China , Neu2000KWL show promising safety profile without serious adverse event single intravenous infusion 6000 mg far beyond therapeutic target dose determine animal model transient ischemic stroke . Very recently , acute endovascular recanalization therapy introduce new standard care care acute ischemic stroke . The present study aim examine efficacy safety Neu2000KWL acute ischemic stroke patient receive endovascular thrombectomy within 8 hour stroke onset .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<criteria>1 . Adults ≥19 year ≤ 80 year 2 . Patients presented hospital onset brain ischemic symptom base last normal state start Endovascular therapy accordance standard practice guideline within 8 hour symptom onset . 3 . NIHSS score screening time point ( admission ) ≥ 8 point 4 . Patients whose activity possible without help others general condition one day ischemic stroke onset . whose Barthel index score exceed 90 point 5 . Patients whose brain CT CT angiography image confirm acute ischemic stroke symptomatic intracranial occlusion screen whose occlusion site consider cause acute ischemic stroke meet follow condition : ① Carotid T L type occlusion ② M1 MCA ③ M1MCA equivalent ( two M2MCAs ) However , anterior temporal artery regard M2 6 . Patients ASPECTS Brain CT without early image hyperenhancement ≥ 6 7 . Patients spontaneously submit write informed consent participation clinical study 1. medical history hypersensitivity aspirin ( salicylate ) , sulfasalazine ( 5ASA ) screening . 2 . Patients meet exclusion criterion image intraarterial recanalization therapy ① CTA Patients whose imaging show site occlusion consider cause acute ischemic stroke meet follow condition : A. MCA + PCA MCA+ACA occlusion Carotid T/L B. occlusion bilateral large artery C. simultaneous infiltration anterior posterior circulation ② absence collateral circulation correspond one following : A . On CT angiography ( MIPCTA ) imaging , absence minimal collateral circulation ≥50 % MCA territory , compare pial fill contralateral side lesion . 3 . Patients whose heart diseases correspond follow condition confirm screening : ① Patients diagnosed myocardial infarction within 6 month screen ② Patients severe arrhythmia evoke clinical symptom ( respiratory difficulty , tachycardia etc . ) within 6 month screen . Patients whose ECG measure stable state emergency room confirm following result : A. pulse rate &lt; 50 &gt; 120 beat per minute B . 2nd 3rd degree AV block confirm . C. congenital acquire QT syndrome confirm D. ventricular preexcitation syndrome confirm 4 . Patients diagnose heart failure ≥ class II accord `` heart failure classification NYHA ( New York Heart Association ) '' screen . `` heart failure classification NYHA ( New York Heart Association ) '' Class I : patient limitation activity ; suffer symptom ordinary activity . Class II : patient slight , mild limitation activity ; comfortable rest mild exertion . Class III : patient marked limitation activity ; comfortable rest . Class IV : patient complete rest , confine bed chair ; physical activity bring . 5 . Patients contraindication contrast medium brain image 6 . Patients receive renal replacement therapy dialysis , due acute chronic renal failure , nephropathy , etc . screen . 7 . Patients diagnose cancer receive cancer therapy within 6 month screen recurrent transitional cancer 8 . Patients show high body temperature 38℃ need antibiotic therapy due medical opinion infectious disease screen . 9 . Patients take pharmacotherapy due liver disease hepatitis , liver cirrhosis etc . screening . 10 . Patients pregnant lactating . However , case woman childbearing potential , patient whose nonpregnancy confirm participate clinical study . 11 . Patients participate clinical study within past 3 month screening time base . However , case participation observatory study without medication , patient participate clinical study . 12 . Patients determine unsuitable participation clinical study due reason .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Neu2000KWL</keyword>
	<keyword>Neuroprotection</keyword>
	<keyword>endovascular therapy</keyword>
	<keyword>glutamate</keyword>
	<keyword>free radical</keyword>
</DOC>